Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome - PubMed (original) (raw)
Review
Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome
Jeffrey S Ross. Adv Anat Pathol. 2009 Jul.
Abstract
A series of multigene classifiers, prognostic and predictive tests have recently been introduced as potentially useful adjuncts for the management of recently diagnosed breast cancer patients. These tests have used both slide-based methods including immunohistochemistry and fluorescence in situ hybridization and nonmorphology driven molecular platforms including quantitative multiplex real time polymerase chain reaction and genomic microarray profiling. In this review, a series of partially and completely commercialized multigene assays are compared with the standard breast cancer clinico-pathologic variables and biomarkers and evaluated as to the level of their scientific validation, current clinical utility, regulatory approval status, and estimated cost-benefit. A comparison of the Oncotype Dx and MammaPrint assays indicates that the Oncotype Dx test has the advantages of an earlier commercial launch in the US, wide acceptance for payment by third party payors, the ease of use of formalin fixed paraffin embedded tissues, a recommendation as ready for use by the American Society of Clinical Oncology Breast Cancer Tumor Markers Update Committee, a continuous rather than dichotomous algorithm, inclusion of both estrogen receptor (ER) and human epidermal growth factor receptor 2 in the mRNA profile, an ability to serve as both a prognostic and predictive test for certain hormonal and chemotherapeutic agents, demonstrated cost-effectiveness in 1 published study, and a high accrual rate for the prospective validation clinical trial (Trial Assigning Individualized Options for Treatment Rx). The MammaPrint assay has the advantages of a 510(k) clearance by the US Food and Drug Administration, a larger gene number which may enhance further utility, and the potentially wider patient eligibility including lymph node-positive, ER-negative, and younger patients being accrued into the prospective trial (the Microarray in Node-negative Disease may Avoid ChemoTherapy). A number of other assays have specific predictive goals most often focused on the efficacy of tamoxifen in ER-positive patients such as the Two-gene Ratio test and the Cytochrome P450 CYP2D6 genotyping assay.
Similar articles
- Commercialized multigene predictors of clinical outcome for breast cancer.
Ross JS, Hatzis C, Symmans WF, Pusztai L, Hortobágyi GN. Ross JS, et al. Oncologist. 2008 May;13(5):477-93. doi: 10.1634/theoncologist.2007-0248. Oncologist. 2008. PMID: 18515733 Review. - Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G. Pentheroudakis G, et al. Breast Cancer Res Treat. 2009 Jul;116(1):131-43. doi: 10.1007/s10549-008-0144-9. Epub 2008 Jul 31. Breast Cancer Res Treat. 2009. PMID: 18668363 Clinical Trial. - Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.
Albain KS, Paik S, van't Veer L. Albain KS, et al. Breast. 2009 Oct;18 Suppl 3:S141-5. doi: 10.1016/S0960-9776(09)70290-5. Breast. 2009. PMID: 19914534 Review. - Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.
Harbeck N, Nimmrich I, Hartmann A, Ross JS, Cufer T, Grützmann R, Kristiansen G, Paradiso A, Hartmann O, Margossian A, Martens J, Schwope I, Lukas A, Müller V, Milde-Langosch K, Nährig J, Foekens J, Maier S, Schmitt M, Lesche R. Harbeck N, et al. J Clin Oncol. 2008 Nov 1;26(31):5036-42. doi: 10.1200/JCO.2007.14.1697. Epub 2008 Aug 18. J Clin Oncol. 2008. PMID: 18711169 - Predicting features of breast cancer with gene expression patterns.
Lu X, Lu X, Wang ZC, Iglehart JD, Zhang X, Richardson AL. Lu X, et al. Breast Cancer Res Treat. 2008 Mar;108(2):191-201. doi: 10.1007/s10549-007-9596-6. Epub 2007 May 22. Breast Cancer Res Treat. 2008. PMID: 18297396
Cited by
- Integrating Genomic Information with Tumor-Immune Microenvironment in Triple-Negative Breast Cancer.
Otohinoyi D, Kuchi A, Wu J, Hicks C. Otohinoyi D, et al. Int J Environ Res Public Health. 2022 Oct 26;19(21):13901. doi: 10.3390/ijerph192113901. Int J Environ Res Public Health. 2022. PMID: 36360779 Free PMC article. - Genome Instability Profiles Predict Disease Outcome in a Cohort of 4,003 Patients with Breast Cancer.
Lischka A, Doberstein N, Freitag-Wolf S, Koçak A, Gemoll T, Heselmeyer-Haddad K, Ried T, Auer G, Habermann JK. Lischka A, et al. Clin Cancer Res. 2020 Sep 1;26(17):4606-4615. doi: 10.1158/1078-0432.CCR-20-0566. Epub 2020 Jun 10. Clin Cancer Res. 2020. PMID: 32522886 Free PMC article. - Breast Cancer Staging: Is TNM Ready to Evolve?
Cadiz F, Gormaz JG, Burotto M. Cadiz F, et al. J Glob Oncol. 2018 Sep;4:1-3. doi: 10.1200/JGO.17.00004. Epub 2017 Aug 28. J Glob Oncol. 2018. PMID: 30241210 Free PMC article. No abstract available. - Gene expression assay and Watson for Oncology for optimization of treatment in ER-positive, HER2-negative breast cancer.
Kim YY, Oh SJ, Chun YS, Lee WK, Park HK. Kim YY, et al. PLoS One. 2018 Jul 6;13(7):e0200100. doi: 10.1371/journal.pone.0200100. eCollection 2018. PLoS One. 2018. PMID: 29979736 Free PMC article. - MammaPrint Feasibility in a Large Tertiary Urban Medical Center: An Initial Experience.
Espinel CF, Keating S, Hibshoosh H, Taback B, Joseph KA, El-Tamer M, Feldman S. Espinel CF, et al. Scientifica (Cairo). 2012;2012:942507. doi: 10.6064/2012/942507. Epub 2012 Dec 31. Scientifica (Cairo). 2012. PMID: 24278759 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials